Residual DNA Quantification Kit-Bovine

Residual DNA refers to unintended DNA fragments from host cells or other sources that remain in the final therapeutic product. The presence of residual DNA in biopharmaceutical products poses significant risks, including immunogenic responses and carcinogenicity, and therefore requires strict control and quantification. Quantification of such residual DNA is critical to ensuring the safety, efficacy, and quality of biopharmaceuticals. Bovine material is often used in biotech drug production, particularly in the form of serum, enzymes, and other components derived from bovine sources. These materials are essential for cell growth and production, but present a risk of introducing bovine DNA into the final product. Regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established strict guidelines for permissible levels of residual DNA in biopharmaceuticals. The Bovine Residual DNA Quantification Kit has been developed specifically for the detection and measurement of bovine DNA contamination in biopharmaceutical products that may use bovine material during the production process.